The global non-Hodgkin lymphoma treatment market size is projected to reach USD 12.57 billion by the end of 2026. The increasing number of regulatory approvals will aid the growth of the market in the coming years. According to a report published by Fortune Business Insights, titled “Non-Hodgkin Lymphoma Treatment Market Size, Share & Industry Analysis, By Therapy (Immunotherapy, Targeted Therapy, Chemotherapy, and Others), By Disease Type (B-cell Lymphoma, and T-cell Lymphoma), By Distribution Channel, and Regional Forecast, 2019-2026,” the market was worth USD 6.60 billion in 2018 and will exhibit a CAGR of 8.4% during the forecast period.
for more information: https://www.fortunebusinessinsights.com/non-hodgkin-lymphoma-treatment-market-102642
Some of the leading companies that are operating in the market include:
- Takeda Pharmaceutical Company Limited
- AstraZeneca
- Bayer AG
- Novartis AG
- Kite Pharma, Inc. / Gilead Sciences, Inc.
- Spectrum Pharmaceuticals, Inc.
- Teva Pharmaceutical Industries Ltd.
- Bristol Myers Squibb Company
- Janssen Pharmaceuticals, Inc.
- Genentech, Inc. (F. Hoffmann-La Roche Ltd)
- CELGENE CORPORATION (Bristol Myers Squibb Company)
- Merck & Co., Inc.
- Kyowa Kirin Co., Ltd.
- AbbVie Inc.
- Sanofi
- Others
Non-Hodgkin lymphoma is a type of cancer that has an effect on the white blood cells of the human body. The disease reduces the immunity of the human body. The severity of the disease has led to a huge emphasis on the R&D of treatment methods. As a result, high investments are being made towards developing efficient treatment methods. The high prevalence of the disease across the world has also caught the eye of investors. There are numerous clinical trials associated with the treatment of the diseases. The focus on therapeutics has risen dramatically in recent years. The increasing prevalence of the disease has compelled companies to look into the non-Hodgkin lymphoma therapeutics and this in turn will contribute to the growth of the market in the coming years.
